Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges

K. S. Saini; I. M. Svane; M. Juan; F. Barlesi; F. André

doi:10.1016/j.annonc.2021.09.020

Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges

K. S. Saini, I. M. Svane, M. Juan, F. Barlesi, F. André

Résultats de recherche: Contribution à un journal › Editorial

4 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	6-12
Nombre de pages	7
journal	Annals of Oncology
Volume	33
Numéro de publication	1
Les DOIs	https://doi.org/10.1016/j.annonc.2021.09.020
état	Publié - 1 janv. 2022

Accès au document

10.1016/j.annonc.2021.09.020

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{86406e77aadd4ae48304d5207282a120,

title = "Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges",

author = "Saini, {K. S.} and Svane, {I. M.} and M. Juan and F. Barlesi and F. Andr{\'e}",

note = "Funding Information: The authors acknowledge the critical review and comments from Brian Hamilton and Carla Sterk of Labcorp Drug Development Inc. None declared. KSS reports consulting fees from the European Commission, and stock and/or other ownership interests in Labcorp Inc. and Quantum Health Analytics SPRL, outside the submitted work. IMS reports advisory board or invited speaker engagement from Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, and Roche; stock and/or other ownership interests in IO Biotech; and institutional grants from Adaptimmune, Enara Bio, Evaxion, Lytix Biopharma, and TILT Biotherapeutics, outside the submitted work. FA reports research funding to his institution from AstraZeneca, Novartis, Pfizer, Eli Lilly, Roche; and travel, accommodations, and expenses from Novartis, Roche, GlaxoSmithKline, AstraZeneca, outside the submitted work. All other authors have declared no conflicts of interest.",

year = "2022",

month = jan,

day = "1",

doi = "10.1016/j.annonc.2021.09.020",

language = "English",

volume = "33",

pages = "6--12",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "1",

}

TY - JOUR

T1 - Manufacture of adoptive cell therapies at academic cancer centers

T2 - scientific, safety and regulatory challenges

AU - Saini, K. S.

AU - Svane, I. M.

AU - Juan, M.

AU - Barlesi, F.

AU - André, F.

N1 - Funding Information: The authors acknowledge the critical review and comments from Brian Hamilton and Carla Sterk of Labcorp Drug Development Inc. None declared. KSS reports consulting fees from the European Commission, and stock and/or other ownership interests in Labcorp Inc. and Quantum Health Analytics SPRL, outside the submitted work. IMS reports advisory board or invited speaker engagement from Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, and Roche; stock and/or other ownership interests in IO Biotech; and institutional grants from Adaptimmune, Enara Bio, Evaxion, Lytix Biopharma, and TILT Biotherapeutics, outside the submitted work. FA reports research funding to his institution from AstraZeneca, Novartis, Pfizer, Eli Lilly, Roche; and travel, accommodations, and expenses from Novartis, Roche, GlaxoSmithKline, AstraZeneca, outside the submitted work. All other authors have declared no conflicts of interest.

PY - 2022/1/1

Y1 - 2022/1/1

UR - http://www.scopus.com/inward/record.url?scp=85119202290&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2021.09.020

DO - 10.1016/j.annonc.2021.09.020

M3 - Editorial

C2 - 34655734

AN - SCOPUS:85119202290

SN - 0923-7534

VL - 33

SP - 6

EP - 12

JO - Annals of Oncology

JF - Annals of Oncology

IS - 1

ER -